Abstract
An object of the present invention is to provide a therapeutic strategy in the solid tumor area and a method and a composition useful therefor to further advance the clinical application of CAR therapy. There is prepared a gene-modified lymphocyte which expresses a chimeric antigen receptor having an EphrinB2 extracellular domain at the antigen recognition site.
Full Text
What is claimed is:
An object of the present invention is to provide a therapeutic strategy in the solid tumor area and a method and a composition useful therefor to further advance the clinical application of CAR therapy. There is prepared a gene-modified lymphocyte which expresses a chimeric antigen receptor having an EphrinB2 extracellular domain at the antigen recognition site.
Timeline
Filed
05/08/2026Published
09/03/2026Granted
Not AvailableIPC Codes(3)
C12N 5/0783:T cells; NK cells; Progenitors of T or NK cells
A61P 35/00:Antineoplastic agents
C07K 14/705:Receptors; Cell surface antigens; Cell surface determinants